Elicio Reports Multiple Complete Responses in Metastatic Pancreatic Cancer After ELI-002 7P and Checkpoint Inhibitor Therapy
Elicio reports three complete responses in metastatic mKRAS pancreatic cancer after ELI-002 7P treatment followed by nivolumab. Company plans Phase 1 combination study.
